

NEW DATA

Nutramigen® A+® with LGG®* and the Allergic March

Berni Canani et al. *J Allergy Clin Immunol* 2017¹


Extensively hydrolyzed casein formula containing *L. rhamnosus* GG plays a role in reducing the occurrence of other allergic manifestations in children with cow's milk protein allergy (CMPA): 3-year randomized controlled trial.[†]

Background

Allergic diseases during infancy are a risk factor for other allergic diseases later on, a concept commonly referred to as the "Allergic March".²⁻⁴

After a 5-year follow-up of infants with CMPA:

- 75% developed allergies to other foods⁵
- 43% developed allergic rhinitis⁵
- 40% developed asthma⁵
- 21% developed atopic dermatitis⁵



Study Objective

- To determine if Nutramigen LGG, an extensively hydrolyzed casein formula + *Lactobacillus rhamnosus* GG (EHCF + LGG) reduces the occurrence of other allergic manifestations compared to Nutramigen without LGG (EHCF) in children with IgE-mediated CMPA, and speeds the development of cow's milk protein tolerance.

Study Design

- This randomized controlled trial included 220 infants 1-12 months of age (median 5 months) with IgE-mediated CMPA, confirmed by double-blind placebo-controlled food challenge.
- Infants received either EHCF + LGG (n=110) or EHCF (n=110) for a period up to 36 months.
- Children were evaluated for allergic manifestations (eczema, rhinoconjunctivitis, urticaria and asthma) and for tolerance acquisition at 12, 24 and 36 months follow-up.

EHCF = extensively hydrolyzed casein formula
LGG = *Lactobacillus rhamnosus* GG

*LGG is a registered trademark of Valio Ltd.

[†]eczema, urticaria, asthma, or rhinoconjunctivitis

NEW DATA

Nutramigen® A+® with LGG®* and the Allergic March

Berni Canani et al. *J Allergy Clin Immunol* 2017¹



Study Results

- Incidence of any allergic manifestation (eczema, rhinoconjunctivitis, urticaria and asthma) within the 36 months is 23% lower in the EHCF + LGG group.
- Additional exploratory analysis suggests there is a lower incidence of any of the individual allergy outcomes in the EHCF + LGG group compared to control:
 - 12% reduction in eczema
 - 17% reduction in rhinoconjunctivitis
 - 13% reduction in urticaria
 - 10% reduction in asthma
- The EHCF + LGG group had higher tolerance acquisition rates at 12, 24 and 36 months.

Clinical Relevance

This randomized controlled trial indicates that EHCF + LGG **can reduce the progression of the Allergic March.**

This study also confirms the higher cow's milk protein tolerance development rates with EHCF + LGG as shown before.^{6,7*}



Recommend Nutramigen® A+® with LGG® for CMPA

To download a full copy of this clinical study go to:

https://eorder.sheridan.com/3_0/app/orders/6658/article.php

AM = allergic manifestation ARD = absolute risk difference

[†] Studied before the addition of LGG culture, DHA and ARA

[‡] Compared to Nutramigen A+ / EHCF alone

[§] Rhinoconjunctivitis, urticaria, eczema, and asthma in a 36 month study

References: 1. Berni Canani R et al. *J Allergy Clin Immunol*. 2017. doi: 10.1016/j.jaci.2016.10.050. In press. 2. Goksör E et al. *Acta Paediatr*. 2016;105:1472-1479. 3. Alduraywish SA et al. *Pediatr Allergy Immunol*. 2017;28:30-37. 4. Somanunt S et al. *Asian Pac J Allergy Immunol*. 2016. doi: 10.12932/AP0825. (Epub ahead of print). 5. Bishop JM et al. *J Pediatr*. 1990;116:862-867. 6. Berni Canani R, Nocerino R, Terrin G et al. *J Allergy Clin Immunol*. 2012;129:580-582. 7. Berni Canani R, Nocerino R, Terrin G et al. *J Pediatr*. 2013;163:771-777.